Hims & Hers Health Inc (NYSE:HIMS) shares traded 0.94% higher at $56.86 on Wall Street last session.
HIMS stock price is now 34.15% away from the 50-day moving average and 79.94% away from the 200-day moving average. The market capitalization of the company currently stands at $12.73B.
With the price target enhanced from $61 to $65, Needham maintained Buy rating for Hims & Hers Health Inc (NYSE: HIMS). On April 29, 2025, TD Cowen Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock keeping its target price maintained at $30, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Chi Michael, Chief Commercial Officer sold 5,100 shares of the company’s stock on Jun 06 ’25. The stock was sold for $285,600 at an average price of $56.00. Upon completion of the transaction, the Chief Commercial Officer now directly owns 256,580 shares in the company, valued at $14.59 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 06 ’25, Officer Chi Michael bought 5,100 shares of the business’s stock. A total of $285,600 was incurred on buying the stock at an average price of $56.00. A total of 10.37% of the company’s stock is owned by insiders.
During the past 12 months, Hims & Hers Health Inc has had a low of $13.47 and a high of $72.98. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 1.59, and a quick ratio of 1.32.
The net profit margin was 9.21% and return on equity was 36.79% for HIMS. The company reported revenue of $586.01 million for the quarter, compared to $278.17 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 110.67 percent.
